Breast Cancer

>

Latest News

PIK3CA-mutant, hormone receptor–positive, HER2-negative, endocrine-resistant advanced breast cancer
Addition of Inavolisib Improves OS in PIK3CA-Mutant, HR+/HER2– Breast Cancer

May 23rd 2025

The phase 3 INAVO120 trial showed that overall survival significantly improved with the addition of inavolisib to palbociclib and fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative, endocrine-resistant advanced breast cancer.

Amanda Brink discusses AI-driven image analysis in HER2 scoring in breast cancer.
Opinion: Artificial Intelligence Enhances Precision in HER2 Scoring for Breast Cancer

May 19th 2025

Anatomical image of a person with a breast tumor
Ribociclib Combo Produces Similar pCR to Chemo in HR+ Breast Cancer

May 18th 2025

Graphic of a breast with a tumor
T-DXd Regimen Improves pCR in Early HER2+ Breast Cancer

May 13th 2025

Line illustration of a clipboard that says "FDA" with an approval mark in front on a cornflower blue background
A Snapshot of April FDA Approvals in Oncology for Nurses and APPs

May 1st 2025

Latest CME Events & Activities

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

Go To PER in Chicago

May 30, 2025 - June 3, 2025

Register Now!

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Register Now!

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

View More

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

View More

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

View More

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

View More

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

View More

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

View More

Annual Hawaii Cancer Conference

January 24-25, 2026

Register Now!

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Register Now!

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

View More

More News